Shanghai Vitalgen Biopharma Co., Ltd.
Clinical trials sponsored by Shanghai Vitalgen Biopharma Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene therapy trial aims to tame Parkinson's symptoms Results expected Sep 2026 (estimated)
- Gene therapy injection aims to halt blindness from rare eye disorder Results expected Dec 2026 (estimated)
- Gene therapy takes on rare eye disease in Second-Eye trial Results expected Jul 2027 (estimated)
- New gene therapy trial hopes to tame rare metabolic disease in kids Results expected Aug 2027 (estimated)
- Gene therapy injection targets Parkinson's in patients with GBA1 mutations Results expected Sep 2027 (estimated)
-
Gene therapy injection aims to control rare brain disease in children
Disease control Not yet recruitingThis early-stage trial tests a new gene therapy called VGN-R08b for children with type III Gaucher disease, a rare genetic disorder affecting the brain and body. The treatment is given as a single injection into the brain's fluid spaces. The study will monitor safety and measure …
Phase 1/2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy takes on rare eye disease in Second-Eye trial
Disease control Not yet recruitingThis study is for people with Bietti's crystalline dystrophy, a rare genetic eye disease that causes vision loss. They have already received the gene therapy VGR-R01 in one eye. Now, researchers want to test if giving the same treatment to the other eye is safe and can improve vi…
Phase 1/2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Gene therapy injection targets Parkinson's in patients with GBA1 mutations
Disease control Not yet recruitingThis early-phase trial tests a gene therapy called VGN-R08b in 17 people with Parkinson's disease who have a GBA1 gene mutation. The therapy is injected directly into the brain's fluid spaces to try to improve symptoms. The main goals are to check safety and see if it works.
Phase 1/2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC